Novo Nordisk A/S (NYSE:NVO) is one of the 10 Best Growth Stocks to Buy With Huge Upside Potential. On June 23, Novo Nordisk A/S (NYSE:NVO) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has given a positive opinion to update the Ozempic label.
The update is based on the new data from the STRIDE trial, which studied people with type 2 diabetes and peripheral artery disease (PAD). The STRIDE trial showed that once-weekly semaglutide improved how far people with PAD and type 2 diabetes could walk. It also improved symptoms and quality of life compared to a placebo.
An elderly couple receiving insulin from a pharmacist, representing healthcare company’s successful pharmaceutical products.
Novo Nordisk A/S says that, if approved by the European Commission, Ozempic will be the only GLP-1 drug proven to reduce risks of cardiovascular death, heart attack, stroke, major kidney events, and improve walking in people with type 2 diabetes. Management is expecting the label update in about two months.
Novo Nordisk A/S is an international healthcare company primarily focused on diabetes care and treatment.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
